Mentions
Extended reach
Total likes
Video views
AI synopsis
Several discussions emphasize the article's assertion that recombinant vaccines provide greater protection against confirmed influenza cases among adults aged 50 to 64. Phrasing such as "relative benefit of recombinant vaccines" and comparisons that reference significant percentages illustrate a deep concern for vaccine effectiveness. The discussions adopt a tone of urgency and relevance, underscoring the importance of advancing vaccine options in the face of evolving health needs.
Many discussions express support for the findings of the study, highlighting the advances in vaccine technology.
The discussions are characterized by a strong curiosity regarding the implications of the study, especially concerning vaccine efficacy in specific age groups.
Participants engage deeply by discussing related questions and potential trials about other vaccines, indicating a strong connection to the topic.
There is a consensus that the research could significantly influence vaccination practices and public health policies, especially for vulnerable populations.
The effectiveness of influenza vaccines varies, but studies comparing the effectiveness of a high-dose quadrivalent recombinant influenza vaccine (Flublok Quadrivalent) with that of a standard-dose vaccine are needed. Read the full Research Summary: https://t.co/71NGgpN8Bn
Original Article: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age https://t.co/71NGgpNGqV #InfectiousDisease https://t.co/FGrwBt6z3g
In a study over two influenza seasons, a high-dose recombinant influenza vaccine was 15% more effective than a standard-dose vaccine in preventing PCR-confirmed influenza in adults between 50 and 64 years of age. Read the full study results: https://t.co/71NGgpN8Bn
Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age 18歳から64歳の成人を対象に、高用量の遺伝子組換え型インフルエンザワクチンと標準用量の鶏卵培養によるワクチンを比較した研究。 米国で2シーズンにわたり実施されたこの研究には、160万人以上が参加した。 https://t.co/yAJ7xaopwr https://t.co/nduFPnOHvI
Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age @NEJM https://t.co/soNhrPpkzi High-dose recombinant vaccine conferred more protection against PCR-confirmed Flu than an egg-based standard-dose vaccine among adults between the ages of 50 and 64 years.
In this episode of Diabetes Core Update, Dr. Neil Skolnik discusses respiratory vaccinations for individuals with diabetes and the growing vaccine hesitancy. Expert guests explore the reasons behind this hesitation and…
@Germa0402 @PaulGanck @John__Boer @HissinkMichel @DominiekC @Ladyjustice1312 @HaHaGentherapie @joyce2104 @splint_s @ErikCumps @ryuuk_ex @HansLandman @cwitteveen1 @Charlot2409 @JanssenJh @LaceyX1989 @Singing_BumbleB @Luketheduke1960 @Bartje46198812 Jouw artikel is uit 2010. De ontwikkeling van vaccins heeft echter niet stilgestaan. Vaccins zijn beter geworden, zie dit artikel uit 2023: https://t.co/N2rPxlx8pH https://t.co/brprZRvuT1
Another important study showing relative benefit of recombinant influenza vaccine over the old egg-based vaccine in those 50-65 this time in a large, well designed pragmatic trial. pubmed.ncbi.nlm.nih.gov/38091531/
Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age | New England Journal of Medicine https://t.co/tM6SQkcySZ
@RealCheckMarker @PoliticalPatel no guarantee of effectiveness against hospitalization or death, significant for the age 65 & older group (the main group usually suffering from the most deleterious effects of influenza). KFF "Splainer" article below study link. 4/ https://t.co/KiFof8pL3q https://t.co/1CVsHuvnzb
@DesertDweller93 @ZhongxingZhang @carter1695 @dviceST @PDSBiotech https://t.co/Wj2vKWC29q Bigger question is whether infectimune can beat high dose flublok head to head. And if so, by how much? And if they are able to prove, how much would it take to license? I’d love to see NIAID fund this trial because I doubt BP will.
Comparando la nueva vacuna recombinante cuadrivalente (Flublok Quadrivalent) contra influenza Vs la vacuna estándar contra influenza:
RT @CarlosdelRio7: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age @NEJM https://t.co/soNhrPpkzi High-dose r…
RT @Dr_Gulfaraz: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age | NEJM https://t.co/saPhQ74gtY
TWiV 1072: Clinical update with Dr. Daniel Griffin
Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age | NEJM https://t.co/saPhQ74gtY
Vacuna contra la gripe (influenza) recombinante o de dosis estándar en menores de 65 años: La vacuna recombinante de dosis alta confirió más protección contra la gripe confirmada por PCR (pero no menos hospitalizaciones) que una vacuna a base de huevo. https://t.co/Sdd2NS1i0Q
RT @DeannaTranPharm: Emerging data suggesting that the recombinant flu vaccine may offer adults 50-64yo better defense against influenza. H…
Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age | NEJM https://t.co/UE2MbPVR48
RT @DeannaTranPharm: Emerging data suggesting that the recombinant flu vaccine may offer adults 50-64yo better defense against influenza. H…
RT @NEJM: The effectiveness of influenza vaccines varies, but studies comparing the effectiveness of a high-dose quadrivalent recombinant i…
RT @NEJM: The effectiveness of influenza vaccines varies, but studies comparing the effectiveness of a high-dose quadrivalent recombinant i…
RT @DeannaTranPharm: Emerging data suggesting that the recombinant flu vaccine may offer adults 50-64yo better defense against influenza. H…
RT @NEJM: The effectiveness of influenza vaccines varies, but studies comparing the effectiveness of a high-dose quadrivalent recombinant i…
RT @NEJM: The effectiveness of influenza vaccines varies, but studies comparing the effectiveness of a high-dose quadrivalent recombinant i…
https://t.co/A9qod6BPlB https://t.co/A2argFXuYx
RT @NEJM: The effectiveness of influenza vaccines varies, but studies comparing the effectiveness of a high-dose quadrivalent recombinant i…
RT @NEJM: The effectiveness of influenza vaccines varies, but studies comparing the effectiveness of a high-dose quadrivalent recombinant i…
RT @NEJM: The effectiveness of influenza vaccines varies, but studies comparing the effectiveness of a high-dose quadrivalent recombinant i…
RT @NEJM: The effectiveness of influenza vaccines varies, but studies comparing the effectiveness of a high-dose quadrivalent recombinant i…
RT @NEJM: The effectiveness of influenza vaccines varies, but studies comparing the effectiveness of a high-dose quadrivalent recombinant i…
RT @NEJM: The effectiveness of influenza vaccines varies, but studies comparing the effectiveness of a high-dose quadrivalent recombinant i…
RT @NEJM: The effectiveness of influenza vaccines varies, but studies comparing the effectiveness of a high-dose quadrivalent recombinant i…
RT @NEJM: The effectiveness of influenza vaccines varies, but studies comparing the effectiveness of a high-dose quadrivalent recombinant i…
RT @NEJM: The effectiveness of influenza vaccines varies, but studies comparing the effectiveness of a high-dose quadrivalent recombinant i…
RT @NEJM: The effectiveness of influenza vaccines varies, but studies comparing the effectiveness of a high-dose quadrivalent recombinant i…
The effectiveness of influenza vaccines varies, but studies comparing the effectiveness of a high-dose quadrivalent recombinant influenza vaccine (Flublok Quadrivalent) with that of a standard-dose vaccine are needed. Read the full Research Summary: https://t.co/71NGgpN8Bn
Ποιο είναι το πιο αποτελεσματικό αντιγριπικό εμβόλιο στις ηλικίες 50 έως 64 ετών [μελέτη] https://t.co/u8fMvEy4L9 https://t.co/CYAI4ywbB9
Emerging data suggesting that the recombinant flu vaccine may offer adults 50-64yo better defense against influenza. However, protection against flu-associated hospitalizations were comparable across vaccine types. https://t.co/y9rEMahHba
RT @CarlosdelRio7: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age @NEJM https://t.co/soNhrPpkzi High-dose r…
RT @CarlosdelRio7: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age @NEJM https://t.co/soNhrPpkzi High-dose r…
Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age @NEJM https://t.co/soNhrPpkzi High-dose recombinant vaccine conferred more protection against PCR-confirmed Flu than an egg-based standard-dose vaccine among adults between the ages of 50 and 64 years.
RT @NEJM: Original Article: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age https://t.co/71NGgpNGqV #Infec…
RT @NEJM: Original Article: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age https://t.co/71NGgpNGqV #Infec…
RT @NEJM: Original Article: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age https://t.co/71NGgpNGqV #Infec…
RT @NEJM: Original Article: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age https://t.co/71NGgpNGqV #Infec…
RT @NEJM: Original Article: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age https://t.co/71NGgpNGqV #Infec…
RT @NEJM: Original Article: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age https://t.co/71NGgpNGqV #Infec…
Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age | NEJM https://t.co/HFz8SZ1mte
RT @gomez_rial5: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age @NEJM https://t.co/DrBh6GteLJ
RT @NEJM: Original Article: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age https://t.co/71NGgpNGqV #Infec…
RT @NEJM: Original Article: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age https://t.co/71NGgpNGqV #Infec…
Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age @NEJM https://t.co/DrBh6GteLJ
RT @NEJM: Original Article: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age https://t.co/71NGgpNGqV #Infec…
Original Article: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age https://t.co/71NGgpNGqV #InfectiousDisease https://t.co/FGrwBt6z3g
RT @carpe_diem0820: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age 18歳から64歳の成人を対象に、高用量の遺伝子組換え型インフルエンザワクチンと…
RT @carpe_diem0820: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age 18歳から64歳の成人を対象に、高用量の遺伝子組換え型インフルエンザワクチンと…
RT @carpe_diem0820: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age 18歳から64歳の成人を対象に、高用量の遺伝子組換え型インフルエンザワクチンと…
Check out this new influenza study: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age| NEJM https://t.co/NM0yhEvVqM
Check out this new influenza study: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age | NEJM https://t.co/Ga81Iq07Xo
Check out this new influenza study: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age | NEJM https://t.co/EvcAEYibnJ
Check out this new influenza study: https://t.co/3xGL4FZxfF
RT @ABsteward:
NEJM: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age https://t.co/Oa4exROyGS インフルエンザワクチンも、将来は組み換え型になるのかしら？
Quadrivalent recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age Quadrivalent recomnbinant protein vaccine (มี haegglutinin มากกว่า standard dose 3 เท่า) มีประสิทธิภาพดีกว่า standard-dose vaccine (ที่ผลิตจากไข่ฟัก) https://t.co/Gq58MFgsff https://t.co/ICzO6CfIP9
RT @carpe_diem0820: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age 18歳から64歳の成人を対象に、高用量の遺伝子組換え型インフルエンザワクチンと…
RT @carpe_diem0820: Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age 18歳から64歳の成人を対象に、高用量の遺伝子組換え型インフルエンザワクチンと…
Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age 18歳から64歳の成人を対象に、高用量の遺伝子組換え型インフルエンザワクチンと標準用量の鶏卵培養によるワクチンを比較した研究。 米国で2シーズンにわたり実施されたこの研究には、160万人以上が参加した。 https://t.co/yAJ7xaopwr https://t.co/nduFPnOHvI
RT @ABsteward:
RT @ABsteward:
RT @ABsteward:
RT @ABsteward:
RT @ABsteward:
高容量の４価リコンビナントインフルエンザワクチンは鶏卵由来の標準ワクチンと比較してPCRで確認されたインフルエンザが15％少なかった。N Engl J Med. 2023; 389: 2245. PMID: 38091531. https://t.co/YUrkpnnZWp
RT @ABsteward:
Recombinant or Standard-Dose Influenza Vac in Adults <65yr;NEJM. 1386 cases of PCR-conf influenza diagn in recombinant-vac; 2435 cases in std-dose. In 50-64yr, 559 (2.00 case/ 1000) test + for influenza in recombinant-vac vs 925 (2.34 case/ 1000) std-dose https://t.co/t0ASVvwcto
呼吸器ウイルスへの新しいワクチンが2本publishされている 特にインフルエンザでは卵ワクチンより15%の減少 造血器腫瘍は治療でも原病でも免疫低下状態になるので、有効性の高いワクチンはありがたいなあ https://t.co/4riw7lXWqD https://t.co/KDumw7vovp
RT @NEJM: In a study over two influenza seasons, a high-dose recombinant influenza vaccine was 15% more effective than a standard-dose vacc…
RT @ABsteward:
RT @NEJM: In a study over two influenza seasons, a high-dose recombinant influenza vaccine was 15% more effective than a standard-dose vacc…
In a study over two influenza seasons, a high-dose recombinant influenza vaccine was 15% more effective than a standard-dose vaccine in preventing PCR-confirmed influenza in adults between 50 and 64 years of age. Read the full study results: https://t.co/71NGgpN8Bn